Nuveen Fund Advisors
VRTX icon

Nuveen Fund Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Nuveen Fund Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,365
Closed -$232K – 161
2018
Q2 		$232K Sell
1,365
-2,934
-68% -$455K 0.29% 137
2018
Q1 		$701K Sell
4,299
-307
-7% -$50.1K 0.32% 92
2017
Q4 		$690K Sell
4,606
-4,870
-51% -$721K 0.2% 139
2017
Q3 		$1.44M Sell
9,476
-1,734
-15% -$261K 0.29% 109
2017
Q2 		$1.45M Sell
11,210
-8,838
-44% -$1.06M 0.23% 138
2017
Q1 		$2.19M Sell
20,048
-3,704
-16% -$326K 0.29% 122
2016
Q4 		$1.75M Sell
23,752
-5,465
-19% -$445K 0.25% 128
2016
Q3 		$2.55M Sell
29,217
-655
-2% -$61.9K 0.36% 97
2016
Q2 		$2.57M Buy
+29,872
New +$2.58M 0.4% 84

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nuveen Fund Advisors's VRTX Position: Q3 2018 in Review

Nuveen Fund Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2018, closing a stake of 1,365 shares — an estimated $232K sold.

Nuveen Fund Advisors first reported a position in VRTX in Q2 2016 and held it in 9 quarters. The position peaked at $2.57M in Q2 2016. 696 funds tracked by Wall St. Rank hold VRTX as of Q3 2018.

  • Nuveen Fund Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Nuveen Fund Advisors sold 1,365 Vertex Pharmaceuticals shares in Q3 2018, an estimated $232K.
  • Nuveen Fund Advisors first reported a position in Vertex Pharmaceuticals in Q2 2016 and held it in 9 quarters.
  • Nuveen Fund Advisors's Vertex Pharmaceuticals position peaked at $2.57M in Q2 2016.
  • 696 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2018.

Based on Nuveen Fund Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.